Spyre Therapeutics (SYRE) CFO sells 15,000 shares after option exercise

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows reported an exercise-and-sale transaction in company stock. On June 25, 2026, he exercised stock options to acquire 15,000 shares of common stock at an exercise price of $14.50 per share, then sold 15,000 shares in open-market transactions.

The sales comprised 10,000 shares at a weighted average price of $87.14 and 5,000 shares at $87.12, with actual trade prices ranging from $86.78 to $87.43. After these trades, he directly held 97,994 shares of common stock, including 67,476 restricted stock units that vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment.

Burrows also continues to hold a stock option originally covering 404,857 shares, with 359,857 option shares remaining after this 15,000‑share exercise. The option had been adjusted for a 1‑for‑25 reverse stock split and vests over several years based on continued employment.

Insights

Equity compensation analyst

CFO executed a routine option exercise and net share sale while retaining a substantial equity stake.

The filing shows Scott L. Burrows exercised options for 15,000 shares at an exercise price of $14.50 and sold 15,000 shares at prices around the high‑$80s. This is a classic exercise‑and‑sell pattern that converts part of his option value into cash.

Post‑transaction, he still holds 97,994 common shares, including 67,476 RSUs that vest in two future installments, plus a large remaining option position of 359,857 shares out of an original 404,857. The visible data suggests ongoing exposure to the company’s equity alongside some liquidity taking.

There is no reference here to a pre‑arranged Rule 10b5‑1 trading plan, so the timing context is not detailed in this filing. Overall, the combination of sales and sizeable remaining holdings makes this look like a routine portfolio and compensation management move rather than a transformative ownership change.

Insider Trade Summary

Exercise and Sale: 15,000 shares ($1.09M approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Burrows Scott L

Role Chief Financial Officer

Sold 15,000 shs ($1.31M)

Approx. gross sale proceeds $1.31M

Approx. exercise cost $218K

Approx. pre-tax spread $1.09M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	15,000	$0.00	$0.00
Exercise	Common Stock	15,000	$14.50	$218K
Sale	Common Stock	5,000	$87.12	$436K
Sale	Common Stock	10,000	$87.14	$871K

Holdings After Transaction: Stock Option (Right to Buy) — 359,857 shares (Direct); Common Stock — 97,994 shares (Direct)

Footnotes (3)

1. F1. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.78 to $87.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
2. F2. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
3. F3. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Key Figures

Shares sold (block 1): 10,000 shares at $87.14 Shares sold (block 2): 5,000 shares at $87.12 Options exercised: 15,000 shares at $14.50 +5 more

8 metrics

Shares sold (block 1) 10,000 shares at $87.14 Open-market sale of common stock on June 25, 2026

Shares sold (block 2) 5,000 shares at $87.12 Open-market sale of common stock on June 25, 2026

Options exercised 15,000 shares at $14.50 Stock option exercise price for common stock

Shares held after trades 97,994 shares Direct common stock ownership following June 25, 2026 transactions

RSUs outstanding 67,476 RSUs Restricted stock units vesting in 2026 and 2027

Option original size 404,857 shares Stock option adjusted for 1-for-25 reverse split

Option shares remaining 359,857 shares Unexercised portion of stock option after 15,000-share exercise

Sale price range $86.78 to $87.43 Range of execution prices for aggregated sales

Key Terms

weighted average price, restricted stock units ("RSUs"), Stock Option (Right to Buy), reverse stock split, +1 more

5 terms

weighted average price financial

"The price reported above is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

restricted stock units ("RSUs") financial

"Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

reverse stock split financial

"have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

vests in monthly installments financial

"with the remaining three quarters vesting in monthly installments over the following three years"

FAQ

What insider transactions did Spyre Therapeutics (SYRE) report for its CFO?

Spyre Therapeutics reported that CFO Scott L. Burrows exercised stock options for 15,000 shares and sold 15,000 common shares in open-market trades on June 25, 2026. These transactions are recorded as routine equity compensation activity rather than a change in company strategy.

How many Spyre Therapeutics (SYRE) shares did the CFO sell and at what prices?

The CFO sold 15,000 Spyre Therapeutics common shares, including 10,000 at a weighted average price of $87.14 and 5,000 at $87.12. Footnotes note actual trade prices ranged between $86.78 and $87.43, reflecting multiple executions within that range.

What is the CFO’s remaining Spyre Therapeutics (SYRE) share ownership after these trades?

After the June 25, 2026 transactions, the CFO directly holds 97,994 Spyre Therapeutics common shares. This total includes 67,476 restricted stock units that convert into shares upon future vesting dates, assuming continued employment with the company.

What stock options in Spyre Therapeutics (SYRE) does the CFO still hold?

The CFO holds a stock option originally covering 404,857 Spyre Therapeutics shares, adjusted for a prior 1‑for‑25 reverse split. After exercising 15,000 shares, 359,857 option shares remain, vesting over several years, contingent on his continued employment with the issuer.

What are the key vesting terms for the CFO’s Spyre Therapeutics (SYRE) RSUs?

The CFO holds 67,476 restricted stock units in Spyre Therapeutics. These RSUs are scheduled to vest in two equal installments on September 1, 2026 and September 1, 2027, provided he remains employed by the company through each respective vesting date.

How were the Spyre Therapeutics (SYRE) sale prices for the CFO’s trades determined?

The filing reports weighted average sale prices of $87.14 for 10,000 shares and $87.12 for 5,000 shares. A footnote explains the shares were sold in multiple transactions, with actual execution prices ranging from $86.78 to $87.43 across the aggregated trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 09:32 PM Accepted by SEC EDGAR 06/26/2026 - 09:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burrows Scott L

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2026		M		15,000	A	$14.5	112,994	D
Common Stock	06/25/2026		S		5,000	D	$87.12	107,994	D
Common Stock	06/25/2026		S		10,000	D	$87.14(1)	97,994(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.5	06/25/2026		M			15,000	(3)	09/01/2033	Common Stock	15,000	$0	359,857	D

Explanation of Responses:

1. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.78 to $87.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

2. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.

3. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)